Shenzhen Juntuo Biotechnology

Shenzhen Juntuo Biotechnology is a clinical-stage biotechnology company specializing in the development of live biotherapeutic products (LBPs) derived from the human gut microbiome. The company focuses on treating immune-mediated and infectious diseases by leveraging its proprietary anaerobic fermentation and strain-specific encapsulation technologies. Its lead candidate, JT001, is a multi-strain microbial consortium designed for the treatment of recurrent Clostridioides difficile infections. Juntuo Bio is also advancing a pipeline targeting ulcerative colitis and other gastrointestinal disorders. The company aims to establish a leading position in the Chinese microbiome market through robust R&D and manufacturing capabilities.